| 영문 | white blood cell(WBC), leukocyte | 한글 | 백혈구 |
|---|---|---|---|
| 설명 | 혈액내에 골수구계세포와 림프계세포, 단핵구계세포를 모두 통틀어 말한다. 백혈구의 증가가 있으면 대개 감염이 있거나, 혹은 탈수현상이 있음을 의미한다. 또한 지나친 백혈구수의 감소는 인체내 면역기능이 떨어져 있음을 의미하며, 다른 질병에 의해 나타나는 이차적인 현상이 아닌지 꼭 진단을 받아보아야 한다. |
||
| 영문 | mast cell | 한글 | 비만 세포 |
|---|---|---|---|
| 설명 | 동물의 결합 조직 가운데 널리 분포하는 세포. 결합조직과 점막조직 내에 있는 호염기성 색소로 이염색성(metachromasia)을 나타내는 과립을 가진 방추형의 세포에 작은 둥근 핵을 가진다. 비만세포의 표면에는 IgE에 대한 수용체가 존재하며, 수용체에 결합한 IgE 분자들끼리 다가의 항원에 의해 서로 연결되면 비만세포 과립탈출 반응이 일어나, 히스타민, 세로토닌, 헤파린 등의 화학전달 물질이 방출되어, 즉시형 알레르기 반응 등의 증상을 일으킨다. 피부, 장막, 혈관 주위, 점막 주변에 있다. |
||
| 영문 | cell-mediated immunity | 한글 | 세포매개면역 |
|---|---|---|---|
| 설명 | 면역이란 신체를 외부의 물질로부터 보호하는 행위를 말한다. 여기에는 특이적 면역과 비특이적 면역의 두 가지가 있다. 비특이적 면역이라함은 특정한 물질에 관계하는 면역이 아니라 특정 대상이 없이 모든 외부 물체에 작용할 수 있는 면역을 말한다. 여기에는 소변의 흐름, 눈물의 흐름, 피부의 비투과성 등의 기계적인 것도 포함되고 피속에 돌아다니는 세포 중에서 비특이적으로 외부의 물질을 포식하는 세포들(예를 들면 큰포식세포(macrophage)의 활동도 포함이 된다. 세포매개면역이란 특이한 물질을 감지할 수 있는 세포를 생성하게 하여 그것으로 하여금 그 물질을 포식하게 하는 것을 말한다. |
||
| NKCF | natural killer cytotoxic factor |
|---|---|
| SCM | Schwann cell membrane; sensation, circulation, and motion; Society of Computer Medicine; soluble cyt... |
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
| NK cell | Natural Killer cell |
| K cell | killer cell |
| NKCF | Natural killer cytotoxic factor |
|---|---|
| LAK cell | lymphokine activated killer cell |
| NK cell | natural killer cell |
| CTL | Cytotoxic T cell |
| NCC | Nonspecific cytotoxic cell |
| cytotoxic cell | Cells of the immune system that inhibit or help to terminate an immune response, e.g., suppressor macrophages and suppressor T-cells. Synonym: cytotoxic cell. (05 Mar 2000) |
|---|---|
| cytotoxic T-cell | <haematology, immunology> Subset of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells (in the context of Class I histocompatibility antigens). (18 Nov 1997) |
| natural killer cell | <haematology, immunology> A certain type of white blood cell that attacks tumour cells and infected body cells by binding to a tumour cell and releasing lethal chemicals. Natural killer cells are thought to play a key role in cancer prevention by killing abnormal cells before they multiply and grow. (16 Dec 1997) |
| natural killer cell stimulating factor | <cytokine> A 75 kD heterodimeric cytokine composed of disulfide-bonded 40 kD and 35 kD subunits that was originally identified by its ability to induce cytotoxic effector cells in synergy with less than optimal concentrations of interleukin-2. It is released by macrophages in response to infection and promotes the activation of cell-mediated immunity. Specifically, IL-12 triggers the maturation of Thl CD4 cells, specific cytotoxic T-lymphocyte responses and an increase in the activity of NK cells and consequently, it is the initiator of cell-mediated immunity. It enhances the lytic activity of NK cells, induces interferon production, stimulates the proliferation of activated T-cells and NK cells. Is secreted by human B lymphoblastoid cells (NC 37). May play a role in controlling immunoglobulin isotype selection as it also inhibits IgE synthesis (even in the presence of anti-IFN monoclonal antibody) and as a growth factor for activated CD4+ and CD8+ T-cells independently of interleukin-2, and for CD56+ NK cells but not resting peripheral blood mononuclear cells or resting or activated tonsillar B-cells. It is likely that interleukin 12 has a major role in protective immunity against viruses and is under study as an immunotherapy in HIV infection. Formerly referred to as cytotoxic lymphocyte maturation factor. Acronym: IL-12 (12 Dec 1998) |
| killer cell | 1. <immunology> Mammalian cells which can lyse antibody coated target cells. They have a receptor for the Fc portion of IgG and are probably of the mononuclear phagocyte lineage, though some may be lymphocytes. Not to be confused with cytotoxic T-cells which recognise targets by other means and are clearly a sub set of T lymphocytes. This confusion exists in the early literature. 2. Natural killer cell are CD3 negative large granular lymphocytes, mediating cytolytic reactions that do not require expression of Class I or II major histocompatibility antigens on the target cell. 3. Lymphokine activated killer cells are NK cells activated by interleukin-2 (LAK cells). (13 Nov 1997) |
| killer T-cell | 1. <immunology> Mammalian cells which can lyse antibody coated target cells. They have a receptor for the Fc portion of IgG and are probably of the mononuclear phagocyte lineage, though some may be lymphocytes. Not to be confused with cytotoxic T-cells which recognise targets by other means and are clearly a sub set of T lymphocytes. This confusion exists in the early literature. 2. Natural killer cell are CD3 negative large granular lymphocytes, mediating cytolytic reactions that do not require expression of Class I or II major histocompatibility antigens on the target cell. 3. Lymphokine activated killer cells are NK cells activated by interleukin-2 (LAK cells). (13 Nov 1997) |
| antireticular cytotoxic serum | An antiserum specific for cells of the reticuloendothelial system. (05 Mar 2000) |
| cytotoxic | <pharmacology> Chemicals that are directly toxic to cells, preventing their reproduction or growth. Cytotoxic agents can, as a side effect, damage healthy, noncancerous tissues or organs which have a high proportion of actively dividing cells, for example, bone marrow, hair follicles. These side effects limit the amount and frequency of drug administration. (16 Dec 1997) |
| cytotoxic drugs | <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells. See: chemotherapy. (13 Nov 1997) |
| cytotoxic reaction | An immunologic (allergic) reaction in which noncytotropic IgG or IgM antibody combines with specific antigen on cell surfaces; the resulting complex initiates the activation of complement which causes cell lysis or other damage, or which, in the absence of complement, may lead to phagocytosis or may enhance T lymphocyte involvement. (05 Mar 2000) |
| cytotoxic t-lymphocyte | A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene: See: Ganciclovir. (09 Oct 1997) |
| cytotoxic T lymphocyte-specific serine protease | <enzyme> Structural sequence given in first source Registry number: EC 3.4.21.- Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II (26 Jun 1999) |
| T cytotoxic cells | Lymphocyte-like effector cells which mediate antibody-dependent cell cytotoxicity. They kill antibody-coated target cells which they bind with their fc receptors. (12 Dec 1998) |
| T-lymphocytes, cytotoxic | Immunised T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (mlc), in vivo during a graft-versus-host (gvh) reaction, or after immunization with an allograft, tumour cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (cml). These cells are distinct from natural killer cells (killer cells, natural) and from killer cells mediating antibody-dependent cell cytotoxicity. (12 Dec 1998) |
| monocytes, activated killer | Monocytes made cytotoxic by ex vivo incubation with cytokines, especially interferon-gamma. Akm cells are used for adoptive immunotherapy in cancer patients. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|